Teniposide with temozolomide for newly diagnosed glioblastoma
Original title: A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
The trial does not list a phase, so we cannot say how far along the testing is.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests two drugs given together to people with a newly diagnosed glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary.
Who this trial is for. This trial is for people with a newly diagnosed glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary whose tumor has a gene marker called MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary promoter unmethylated. It tests the drug teniposide given along with the drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. Everyone in the trial gets both drugs. People go to the hospital for checks during each round of treatment.
Where it stands. The trial has not reported any results. It is measuring how well the two drugs work against the tumor. It is also tracking the health problems and side effects people have while taking them. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If this is your situation, this trial may be worth asking your care team about. They can look at your case and tell you if it might fit. Right now it is a question being studied, not a treatment your own doctor can give you.
What it doesn't mean: This does not mean the two drugs together are proven to work. A trial is a test, not a treatment you can count on. Being in a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, October 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.